Replies to post #74880 on Biotech Values

[DewDiligence]

VRTX /PROVE-3 results: The "24+24" arm is very problematic anyway because telaprevir's side effects after 12 weeks treatment are pretty much unacceptable.

Exactly right. Although the 24+24 arm of PROVE-3 had significantly fewer relapses than the 12+12 arm, the ITT SVR rate of the two arms ended up being the same because the 24+24 arm had so many more dropouts.

It’s becoming increasingly clear that the standard treatment regimen for most new HCV regimens is apt to be 24 weeks of total treatment if a patient has a durable RVR and 48 weeks if not.